Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 10Unknown 5Recruiting 4Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 32Head and Neck Neoplasms 24Glioblastoma 24Squamous Cell Carcinoma of Head and Neck 22Breast Neoplasms 21Lymphoma 17Brain Neoplasms 17Rectal Neoplasms 16Prostatic Neoplasms 15Lymphoma, Non-Hodgkin 14Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Follicular 11Gliosarcoma 11Esophageal Neoplasms 11Central Nervous System Neoplasms 11Adenocarcinoma Of Esophagus 11Pancreatic Neoplasms 10Melanoma 10Lymphoma, Large B-Cell, Diffuse 10Hodgkin Disease 10Neoplasm Metastasis 9Multiple Myeloma 9Neoplasms, Plasma Cell 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Acute 8Burkitt Lymphoma 8Sarcoma 7

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6Megestrol Acetate 4niraparib 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × Radiotherapy × Clear all
NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡